BAYER AG NA O.N.
Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST
Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?
Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.
Read
Commented by André Will-Laudien on April 7th, 2026 | 07:35 CEST
Fertilizer Crisis: Supply Chain Collapse Threatens Bayer, Nestlé, MustGrow, and K+S! Where are the Opportunities for Investors?
The escalation involving Iran has thrown global supply chains and the fertilizer and food sectors into a state of emergency, as sanctions and security risks are crippling exports of key raw materials. Iran, a key producer of phosphate-based fertilizers and potash products, is temporarily out of the picture, leading to price spikes of up to 40% in the agricultural sector. Bayer is struggling with rising production costs for its agrochemicals division, which is putting extreme pressure on margins. Even Nestlé is increasingly facing raw material shortages for animal feed and packaging materials. The situation regarding supply security in Europe is at risk in the medium term, as inflationary pressure on food prices is noticeably increasing. MustGrow is positioning itself as a game-changer with organic fertilizer alternatives that are scalable regardless of geopolitical hotspots and promise rapid revenue growth. Kali + Salz is benefiting massively from the demand for potash fertilizer, as European inventories shrink and demand from agriculture explodes.
Read
Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer
The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.
Read
Commented by Mario Hose on March 25th, 2026 | 07:00 CET
The Mustard Revolution Is Here! How the Newcomer MustGrow Is Challenging Giants Bayer and K+S
We may already be, or soon find ourselves, at a dangerous crossroads in world history, where the mere availability of food becomes a decisive factor of power. While headlines are dominated by blocked shipping routes like the Strait of Hormuz and fertilizer shortages, a new alliance for supply security is forming on the stock market. Companies such as Bayer and K+S find themselves in a technical chart situation that raises only one key question: Is this a good entry opportunity? At the same time, the innovative pioneer MustGrow Biologics is preparing to disrupt the market from the ground up with its patented mustard-based technology. In this report, we analyze why the combination of established chemical power, strategic raw materials, fertilizers, and a biological revolution could stabilize your portfolio right now. Those who fail to take a closer look may miss the moment when the course for the coming years is set.
Read
Commented by Armin Schulz on March 20th, 2026 | 08:20 CET
Fertilizer Crisis Triggered by the Iran War: Why Bayer, MustGrow Biologics, and K+S Offer the Perfect Portfolio Mix
When bombs fall in the Persian Gulf, the global agricultural economy trembles. The recent military strikes against Iran have thrown the fertilizer markets into turmoil. Prices for nitrogen and ammonia are skyrocketing, and shares of North American corporations are surging by double digits. Regardless of the acute geopolitical upheaval, the industry is undergoing a fundamental transformation. While one half of the sector is still cashing in on the short-term gains from the crisis, the other has long been driving forward the vision of sustainable agriculture, spurred by regulatory pressure. Three companies show where the journey is headed: agricultural giant Bayer, agricultural biotechnology company MustGrow Biologics, and fertilizer specialist K+S.
Read
Commented by Armin Schulz on March 11th, 2026 | 07:20 CET
Three trends, one goal: How Bayer, MustGrow Biologics, and BASF are turning the agricultural revolution into a profit opportunity
Three trends are currently driving the global agricultural economy: skyrocketing fertilizer prices, regulatory pressure to preserve biodiversity, and the insatiable hunger of a growing population. As farmers navigate between existential fears and the pressure to go green, a billion-dollar transformation of industry is looming. Old chemistry is reaching its limits, while demand for biological alternatives and precision technologies is reaching an all-time high. Amid this tension between volatility and opportunity, the future of plant production is being reshaped. We take a look at how Bayer, MustGrow Biologics, and BASF are driving this transformation and could benefit from it.
Read
Commented by Fabian Lorenz on March 6th, 2026 | 07:20 CET
SHORT SQUEEZE at Gerresheimer? Will Bayer and MustGrow soon grow together?
While the stock market digests the Iran war and rising energy prices, Gerresheimer's share price is suddenly rising noticeably. There is no news. Is a short squeeze possible? Short sellers had even expanded their positions recently. Bayer does not (yet) hold a stake in MustGrow. However, the Leverkusen-based company has acquired a license to distribute the innovative agricultural products and is investing in their approval. This could enable MustGrow shares to make the leap from hidden gem to high flyer. Management has recently expressed optimism. The stock appears to be undervalued. After the sharp setback in recent weeks, analysts see upside potential for Bayer again. However, shareholders should not expect much in terms of revenue and profit growth in the current year. Cash flow is even expected to be significantly negative.
Read
Commented by Mario Hose on March 2nd, 2026 | 08:00 CET
Feeding a Growing World: Bayer, K+S, and MustGrow Biologics! Mustard, as a biological innovation, is transforming the agriculture of tomorrow!
Global agriculture faces mounting structural pressure. More than 8 billion people live on Earth today, and every person needs food every day. But the fields where we can grow food are getting smaller. Traditional methods of agriculture are losing acceptance, as synthetic fertilizers and chemical crop protection agents face stricter environmental oversight worldwide. That is why companies such as MustGrow Biologics, Bayer, and K+S are becoming increasingly important. These companies are working on a new type of agriculture. They are attempting to strike a balance: they aim to ensure good harvests while also protecting nature. The smaller innovator, MustGrow Biologics, exemplifies the shift toward effective biological alternatives in modern agriculture.
Read
Commented by Fabian Lorenz on March 2nd, 2026 | 07:40 CET
First Majestic Silver hits an all-time high! Could Silver Viper Minerals be next? Resistance at Bayer!
The silver rally is far from over, as the price of the precious metal has stabilized at a high level of USD 90 per ounce, enabling the industry to generate high revenues. First Majestic is an impressive example, with investors celebrating record figures that pushed the stock to a new all-time high last week. Similarly, Silver Viper Minerals is drawing attention, offering clear growth targets and fueling takeover speculation. The CEO made a convincing case at an investor conference last week, outlining the Canadians’ 2026 motto: “drill, drill, drill.” At the same time, the company aims to grow through acquisitions, likely ensuring an exciting news flow. Meanwhile, at Bayer, the focus is back on glyphosate. Recent optimism about an end to the saga had driven the stock higher, but now, resistance is emerging.
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read